Back

에스엘에스바이오 KOSDAQ

246250

Suggest a tag

Watch

Notes Naver Finance

Meeting voting results

Annual 2026.03.27

Participation 42.2% Minority 3.8% Max. opposition 2.5% DART

1 제19기(2025.01.01~2025.12.31) 재무제표 승인 Approved Approval 99.7%
2-1 사외이사 류제만 선임의 건 Approved Approval 99.5%
2-2 기타비상무이사 김종수 선임의 건 Approved Approval 99.2%
3-1 감사 정명석 선임의 건 Approved Approval 97.5%
4 정관 변경의 건 Approved Approval 99.5%
5 이사 보수한도 승인의 건 Approved Approval 98.8%
6 감사 보수한도 승인의 건 Approved Approval 99.2%

Previous meeting results

Financial indicators

Market cap

302 × 100M KRW

PBR

5.13

PER

ROE

-48.68%

Dividend yield

Debt-to-equity ratio

47.1%

Share price history

Share price

Daily close

Latest close

5-year high

5-year low

Use the period buttons above to adjust the range.

Shareholder distribution

Based on 2026 First-quarter report (2026-03-31)

Controlling shareholders total

39.50%

Minority shareholders (excl. related parties)

52.43%

Large outside holders (1%+)

8.07% (7 people)

Treasury shares

0.00%

Total shareholders

9,769 people

Annual earnings Trend

Financial statements

Separate · this company only

Income figures cover the quarter, not the year to date.

에스엘에스바이오 — Quarterly Income statement
Item	24/3 Separate	24/6 Separate	24/9 Separate	24/12 Separate	25/3 Separate	25/6 Separate	25/9 Separate	25/12 Separate	26/3 Separate	26/6 Separate
Revenue	20.5 × 100M KRW	23.8 × 100M KRW	21.2 × 100M KRW	18.3 × 100M KRW	17.5 × 100M KRW	15.9 × 100M KRW	3 × 100M KRW	3.4 × 100M KRW	9.6 × 100M KRW	12.9 × 100M KRW
Operating profit	7,916 × 10,000 KRW	3 × 100M KRW	1.1 × 100M KRW	-2 × 100M KRW	-2.2 × 100M KRW	-6.7 × 100M KRW	-18 × 100M KRW	-14.1 × 100M KRW	-9.5 × 100M KRW	-
Net income	1.3 × 100M KRW	3.5 × 100M KRW	1.6 × 100M KRW	-3.1 × 100M KRW	-2 × 100M KRW	-11.9 × 100M KRW	-18.7 × 100M KRW	-16.5 × 100M KRW	-9.4 × 100M KRW	-
Operating margin	3.86%	12.49%	5.07%	-10.70%	-12.51%	-42.35%	-608.82%	-413.63%	-99.23%	-
EPS	-	-	-	-	-	-	-	-	-	-

에스엘에스바이오 — Annual Income statement
Item	2022 Separate	2023 Separate	2024 Separate	2025 Separate
Revenue	107.5 × 100M KRW	90.2 × 100M KRW	83.7 × 100M KRW	39.8 × 100M KRW
Operating profit	24.2 × 100M KRW	10.3 × 100M KRW	2.9 × 100M KRW	-41.1 × 100M KRW
Net income	28.3 × 100M KRW	14.3 × 100M KRW	3.4 × 100M KRW	-49 × 100M KRW
Operating margin	22.54%	11.43%	3.44%	-103.05%
EPS	-	-	-	-

Balance sheet figures are quarter-end balances.

에스엘에스바이오 — Quarterly Balance sheet
Item	24/3 Separate	24/6 Separate	24/9 Separate	24/12 Separate	25/3 Separate	25/6 Separate	25/9 Separate	25/12 Separate	26/3 Separate	26/6 Separate
Total assets	175.7 × 100M KRW	174.6 × 100M KRW	175.6 × 100M KRW	163.6 × 100M KRW	157.8 × 100M KRW	144.6 × 100M KRW	126.9 × 100M KRW	112.3 × 100M KRW	100.9 × 100M KRW	97.2 × 100M KRW
Current assets	114.6 × 100M KRW	114.7 × 100M KRW	116.3 × 100M KRW	97.9 × 100M KRW	94.6 × 100M KRW	82.1 × 100M KRW	61.8 × 100M KRW	45.1 × 100M KRW	36 × 100M KRW	33.2 × 100M KRW
Non-current assets	61.1 × 100M KRW	60 × 100M KRW	59.3 × 100M KRW	65.7 × 100M KRW	63.1 × 100M KRW	62.5 × 100M KRW	65.1 × 100M KRW	67.1 × 100M KRW	64.9 × 100M KRW	64 × 100M KRW
Total liabilities	43.4 × 100M KRW	38.8 × 100M KRW	38.5 × 100M KRW	38.5 × 100M KRW	34.5 × 100M KRW	33.4 × 100M KRW	34.4 × 100M KRW	35.9 × 100M KRW	33.9 × 100M KRW	39.4 × 100M KRW
Current liabilities	18.4 × 100M KRW	14.1 × 100M KRW	13.9 × 100M KRW	14.7 × 100M KRW	11.7 × 100M KRW	11.7 × 100M KRW	14.3 × 100M KRW	15.8 × 100M KRW	16.6 × 100M KRW	24.1 × 100M KRW
Non-current liabilities	25.1 × 100M KRW	24.8 × 100M KRW	24.7 × 100M KRW	23.7 × 100M KRW	22.8 × 100M KRW	21.7 × 100M KRW	20.1 × 100M KRW	20.1 × 100M KRW	17.3 × 100M KRW	15.4 × 100M KRW
Total equity	132.3 × 100M KRW	135.8 × 100M KRW	137.1 × 100M KRW	125.1 × 100M KRW	123.2 × 100M KRW	111.2 × 100M KRW	92.5 × 100M KRW	76.4 × 100M KRW	67 × 100M KRW	57.8 × 100M KRW
Share capital	38.4 × 100M KRW	38.4 × 100M KRW	76.7 × 100M KRW	76.7 × 100M KRW	76.7 × 100M KRW	76.7 × 100M KRW	76.7 × 100M KRW	76.7 × 100M KRW	76.7 × 100M KRW	76.7 × 100M KRW
Capital surplus	51.5 × 100M KRW	51.5 × 100M KRW	12.9 × 100M KRW	12.9 × 100M KRW	12.9 × 100M KRW	12.9 × 100M KRW	12.9 × 100M KRW	12.9 × 100M KRW	12.9 × 100M KRW	12.9 × 100M KRW
Other equity	-	-	-	-	-	-7.1 × 100M KRW	-7.1 × 100M KRW	-7.1 × 100M KRW	-7.1 × 100M KRW	-
Accumulated other comprehensive income	-1,191 × 10,000 KRW	-1,171 × 10,000 KRW	-1,429 × 10,000 KRW	-79 × 10,000 KRW	728 × 10,000 KRW	-986 × 10,000 KRW	-986 × 10,000 KRW	2,466 × 10,000 KRW	2,466 × 10,000 KRW	8,103 × 10,000 KRW
Retained earnings	40.6 × 100M KRW	44.1 × 100M KRW	45.7 × 100M KRW	42.6 × 100M KRW	40.6 × 100M KRW	28.7 × 100M KRW	10 × 100M KRW	-6.4 × 100M KRW	-15.8 × 100M KRW	-25.5 × 100M KRW

에스엘에스바이오 — Annual Balance sheet
Item	2022 Separate	2023 Separate	2024 Separate	2025 Separate
Total assets	117.5 × 100M KRW	178.4 × 100M KRW	163.6 × 100M KRW	112.3 × 100M KRW
Current assets	-	-	97.9 × 100M KRW	45.1 × 100M KRW
Non-current assets	-	-	65.7 × 100M KRW	67.1 × 100M KRW
Total liabilities	50.5 × 100M KRW	43.7 × 100M KRW	38.5 × 100M KRW	35.9 × 100M KRW
Current liabilities	-	-	14.7 × 100M KRW	15.8 × 100M KRW
Non-current liabilities	-	-	23.7 × 100M KRW	20.1 × 100M KRW
Total equity	67.1 × 100M KRW	134.7 × 100M KRW	125.1 × 100M KRW	76.4 × 100M KRW
Share capital	-	-	76.7 × 100M KRW	76.7 × 100M KRW
Capital surplus	-	-	12.9 × 100M KRW	12.9 × 100M KRW
Other equity	-	-	-	-7.1 × 100M KRW
Accumulated other comprehensive income	-	-	-79 × 10,000 KRW	2,466 × 10,000 KRW
Retained earnings	-	-	42.6 × 100M KRW	-6.4 × 100M KRW

Quarterly cash flow is calculated from changes in cumulative totals.

에스엘에스바이오 — Quarterly Cash flow statement
Item	24/3 Separate	24/6 Separate	24/9 Separate	24/12 Separate	25/3 Separate	25/6 Separate	25/9 Separate	25/12 Separate	26/3 Separate	26/6 Separate
Operating cash flow	2.3 × 100M KRW	4.5 × 100M KRW	7.2 × 100M KRW	3.2 × 100M KRW	2 × 100M KRW	-3.1 × 100M KRW	-7 × 100M KRW	-13.8 × 100M KRW	-8 × 100M KRW	-8.2 × 100M KRW
Investing cash flow	-3.5 × 100M KRW	-2.2 × 100M KRW	-1.7 × 100M KRW	2.4 × 100M KRW	-6,408 × 10,000 KRW	786 × 10,000 KRW	9.2 × 100M KRW	10.8 × 100M KRW	9.4 × 100M KRW	20.5 × 100M KRW
Financing cash flow	-1.5 × 100M KRW	-5.3 × 100M KRW	-1.8 × 100M KRW	-10.5 × 100M KRW	-1.5 × 100M KRW	-1.5 × 100M KRW	-1.6 × 100M KRW	-1.6 × 100M KRW	-1.6 × 100M KRW	3.4 × 100M KRW

에스엘에스바이오 — Annual Cash flow statement
Item	2022 Separate	2023 Separate	2024 Separate	2025 Separate
Operating cash flow	-	-	17.3 × 100M KRW	-21.9 × 100M KRW
Investing cash flow	-	-	-5 × 100M KRW	19.4 × 100M KRW
Financing cash flow	-	-	-19 × 100M KRW	-6.1 × 100M KRW

ROE is net income divided by closing equity. PER and PBR are omitted when the accounting scope or price date is unverified.

에스엘에스바이오 — Quarterly Investment indicators
Item	24/3 Separate	24/6 Separate	24/9 Separate	24/12 Separate	25/3 Separate	25/6 Separate	25/9 Separate	25/12 Separate	26/3 Separate	26/6 Separate
Debt-to-equity ratio	32.83%	28.60%	28.10%	30.73%	28.02%	30.04%	37.20%	47.07%	50.61%	68.21%

에스엘에스바이오 — Annual Investment indicators
Item	2022 Separate	2023 Separate	2024 Separate	2025 Separate
ROE	42.15%	10.65%	2.68%	-64.23%
Debt-to-equity ratio	75.28%	32.46%	30.73%	47.07%
Separate total assets	-	-	-	-
PER	-	-	-	-
PBR	-	-	-	-
Dividend per share	-	KRW 25	-	-

Property holdings

Total book value

12 × 100M KRW

Total assessed land value

Ratio to market cap

4.1%

Land

0 records

Buildings

0 records

Category	Location	Use	Area	Book value	Assessed land value
기타 Unverified	경기도 수원시 영통구 창룡대로 260, 7층(이의동, 광교센트럴비즈타워)	본사와 연구소	-	12 × 100M KRW	-

Ownership structure

Is a listed company shown as unlisted?

Articles of incorporation analysis

Analysis date 2026.06.19 02:25 | Last amended 2024.08.08

Unverified Original articles of incorporation

주주친화

신주의 동등배당: 배당기준일 전 유상증자, 무상증자 및 주식배당으로 발행한 주식에 대해 동등배당을 규정 (제12조)

주주비친화

집중투표제 명시적 배제: 2인 이상의 이사를 선임하는 경우 상법 제382조의2의 집중투표제를 적용하지 않아 소수주주 이사 선임 가능성을 제한 (제34조③)
이사회 결의만으로 200억원 전환사채 제3자 배정: 경영상 목적 등을 이유로 주주 외의 자에게 전환사채를 발행할 수 있어 경영권 분쟁 시 우호지분 확보 수단이 될 수 있음 (제18조①)
이사회 결의만으로 100억원 신주인수권부사채 제3자 배정: 긴급 자금조달·기술도입 등 사유로 주주 외의 자에게 신주인수권부사채를 발행할 수 있음 (제19조①)
이사 책임감경 조항: 최근 1년 보수액의 6배, 사외이사는 3배를 초과하는 손해배상책임을 면제할 수 있어 주주대표소송의 실효성을 낮출 수 있음 (제38조의2)
이사 임기 3년 고정: 상법상 최장 수준의 임기를 정관에 두어 이사회 교체 속도를 늦출 수 있음 (제35조①)

기타 주목 조항

우선주 보통주 전환: 우선주 존속기간은 발행일로부터 10년 이내에서 이사회가 정하고, 기간 만료와 동시에 보통주식으로 전환 (제9조의2⑤)
보궐선임 이사 임기: 보궐선임된 이사의 임기는 전임자의 잔여기간으로 함 (제35조②)
감사 분리상정: 감사 선임·해임 의안은 이사 선임·해임 의안과 별도로 상정하여 의결 (제46조②)

Board of directors

Number of directors

3–6 people

Director term

3 years (Fixed)

Remaining term for replacements

Staggered board

None

Cumulative voting

Separate chair and CEO

Gender diversity requirement

Director liability limitation

Exemption above 6.0×

Auditors

Number of auditors

At least 1 person

Auditor term

3 years (Fixed)

Shareholder meetings and dividends

Meeting notice period

14 days

Written voting

Electronic voting

Dividend record date

이사회 결의로 정하는 배당기준일

Third-party allotment limit by board resolution alone

Convertible bonds (CB)

200 × 100M KRW

Bonds with warrants (BW)

100 × 100M KRW

Compensation basis

Director: 주주총회 결의로 정한다
Auditors: 이사의 보수 규정을 준용하되 이사 보수결정 의안과 구분하여 상정·의결한다
Retirement payments: 주주총회 결의를 거친 임원퇴직금지급규정에 의한다

Executive compensation

Based on 2025 Annual report

Total compensation

2 × 100M KRW

Executives

5 people

Average per executive

4,964 × 10,000 KRW

Total dividends

Compensation / dividends

No dividend

Controlling shareholders

Name	Relationship	Age	Ownership
이영태	Self	Age 72	15.53%
문해란	대주주	-	13.19%
에스에스메디피아	특수관계법인	-	9.43%
조미라	특수관계법인 임원	-	1.35%
김봉휘	임원	Age 55	0.43%

Holders of 5% or more

Holder	Holding ratio	Shares held	Change in ownership	Reason for filing	Report type	Filing date
이영태	36.49%	5,600,331	-2.93%	단순 장내 취득에 의한 지분율의 변동 무장증자 신주 배정으로 인한 발행 주식수의 변동	일반	2025-03-17
이영태	39.42%	6,050,331	+0.84%	단순 장내 취득에 의한 지분율의 변동 무장증자 신주 배정으로 인한 발행 주식수의 변동	일반	2024-12-18
이영태	38.58%	2,960,785	+0.14%	단순 장내 취득에 의한 지분율의 변동	일반	2024-07-03

Auditors

Analysis date 2026.08.27 12:30

Auditor	Type	Term start	Term end	Tenure	D-day
김평협	Auditor	-	2026.03.29	2 years	Expired
정명석	Auditor	-	2029.03.27	-	D-903

Executives

Name	Position	Category	Age	Term end
조현찬	기타비상무이사	Other non-executive director	Age 75	D-536
김종수	CTO	Other non-executive director	Age 73	Expired
이영태	대표이사	Inside director	Age 72	D-541
김평협	감사	감사	Age 69	Expired
이정일	사외이사	Outside director	Age 68	Expired
김봉휘	상무이사	미등기	Age 55	-

DART disclosures

Loading disclosures…

에스엘에스바이오 KOSDAQ

Meeting voting results Collapse Meeting voting results

Financial indicators Collapse Financial indicators

Share price history 10 years 5 years 3 years 1 year 3 months 1 week Collapse Share price history

Shareholder distribution Collapse Shareholder distribution

Annual earnings Trend Collapse Annual earnings

Financial statements Collapse Financial statements

Property holdings Collapse Property holdings

Ownership structure Collapse Ownership structure

Articles of incorporation analysis Collapse Articles of incorporation analysis

주주친화

주주비친화

기타 주목 조항

Board of directors

Auditors

Shareholder meetings and dividends

Third-party allotment limit by board resolution alone

Compensation basis

Executive compensation Collapse Executive compensation

Controlling shareholders Collapse Controlling shareholders

Holders of 5% or more Collapse Holders of 5% or more

Auditors Collapse Auditors

Executives Collapse Executives

DART disclosures Collapse DART disclosures

Meeting voting results

Financial indicators

Share price history

Shareholder distribution

Annual earnings Trend

Financial statements

Property holdings

Ownership structure

Articles of incorporation analysis

Executive compensation

Controlling shareholders

Holders of 5% or more

Auditors

Executives

DART disclosures